Innate Pharma is a biotechnology business based in the US. Innate Pharma shares (IPHA) are listed on the NASDAQ and all prices are listed in US Dollars. Innate Pharma employs 213 staff and has a trailing 12-month revenue of around $57 million.
How to buy Innate Pharma stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – IPHA. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Commission-free trading
- Commission-free crypto
- No minimum account balance
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Innate Pharma stock price (NASDAQ: IPHA)Use our graph to track the performance of IPHA stocks over time.
Innate Pharma shares at a glance
|Latest market close||$3.45|
|52-week range||$1.90 - $4.10|
|50-day moving average||$2.77|
|200-day moving average||$2.68|
|Wall St. target price||$8.06|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.69|
Buy Innate Pharma stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Innate Pharma stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Innate Pharma price performance over time
|1 week (2023-01-23)||-1.71%|
|1 month (2022-12-30)||-7.51%|
|3 months (2022-10-28)||60.47%|
|6 months (2022-07-29)||7.81%|
|1 year (2022-01-28)||-3.90%|
|2 years (2021-01-29)||-15.65%|
|3 years (2020-01-30)||6.9|
|5 years (2018-01-26)||N/A|
Innate Pharma financials
|Revenue TTM||$57 million|
|Gross profit TTM||$-22,301,000|
|Return on assets TTM||-4.3%|
|Return on equity TTM||-17.31%|
|Market capitalisation||$302.8 million|
TTM: trailing 12 months
Innate Pharma share dividends
We're not expecting Innate Pharma to pay a dividend over the next 12 months.
Innate Pharma share price volatility
Over the last 12 months, Innate Pharma's shares have ranged in value from as little as $1.9 up to $4.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Innate Pharma's is 0.3569. This would suggest that Innate Pharma's shares are less volatile than average (for this exchange).
Innate Pharma overview
Innate Pharma S. A. , a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S. A.
Innate Pharma in the news
Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers
Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology
Frequently asked questionsWhat percentage of Innate Pharma is owned by institutions?
Currently 1.178% of Innate Pharma shares are held by institutions. How many people work for Innate Pharma?
Latest data suggests 213 work at Innate Pharma. When does the fiscal year end for Innate Pharma?
Innate Pharma's fiscal year ends in December. Where is Innate Pharma based?
Innate Pharma's address is: 117, Avenue de Luminy, Marseille, France, 13009 What is Innate Pharma's ISIN number?
Innate Pharma's international securities identification number is: US45781K2042 What is Innate Pharma's CUSIP number?
Innate Pharma's Committee on Uniform Securities Identification Procedures number is: 45781K204
More guides on Finder
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert